ASCO 2023 | PSMA PET guided salvage RT among patients with prostate cancer in the post-prostatectomy setting

Jeremie Calais, MD, MSc, University of California, Los Angeles, CA, provides an overview on a single center post-hoc analysis of 5 prospective studies evaluating PSMA PET guided salvage radiotherapy (sRT) among patients with prostate cancer in the post-prostatectomy setting. The analysis included 176 patients who received sRT within 3 months of PSMA PET and had at least 12 months of follow-up. PSMA PET was positive in 73% of patients, with varying degrees of metastasis. Treatment fields for sRT were guided by PSMA PET findings, and concurrent androgen deprivation therapy (ADT) was administered in some cases. After a median follow-up of 32 months, 45% of patients did not develop biochemical recurrence or imaging relapse following sRT. The study suggests that PSMA PET-guided sRT is effective for treating both pelvic and extrapelvic recurrent PCa. Further research is needed to explore patient outcomes in this population. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.